Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients
Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients
阿斯蘭製藥報告了Eblasakimab在經歷過Dupilumab的特應性皮炎患者中進行Eblasakimab的2期研究的中期結果
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。